Its intended for adults with an initial body mass index (BMI) of 30 kg/m or greater (obese), or for those with a BMI of 27 kg/m or greater (overweight) who also have at least one weight-related comorbidity
By activating the GLP-1 receptors, these medications help control blood sugar, reduce appetite, and improve insulin sensitivity
One of these trials [4] involved healthy adults, including both normoglycemic individuals and those with prediabetes, and used a randomised, double-blind, placebo-controlled design to test Nextida GCs impact on GLP-1 levels, glucose response, and insulin regulation
Understanding potential drug interactions helps healthcare providers make informed decisions about medication combinations and monitoring requirements
/research Phase 2 trials
Semaglutida de grado de investigacin fabricada en instalaciones cGMP en Dallas, Texas